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O B J E C T I V E S The aim of this study was to further explore the interplay between smoking status,
coronary artery calcium (CAC), and all-cause mortality.
B A C KG ROUND Prior studies have not directly compared the relative prognostic impact of CAC in
smokers versus nonsmokers. In particular, although a calcium score of zero (CAC  0) is a known
favorable prognostic marker, whether smokers with CAC  0 have as good a prognosis as nonsmokers
with CAC  0 is unknown. Given that computed tomography (CT) screening for lung cancer appears
effective in smokers, the relative prognostic implications of visualizing any CAC versus no CAC on such
screening also deserve study.
METHOD S Our study cohort consisted of 44,042 asymptomatic individuals referred for noncontrast
cardiac CT (age 54  11 years, 54% men). Subjects were followed for a mean of 5.6 years. The primary
endpoint was all-cause mortality.
R E S U L T S Approximately 14% (n  6,020) of subjects were active smokers at enrollment. There were 901
deaths (2.05%) overall, with increased mortality in smokers versus nonsmokers (4.3% vs. 1.7%, p  0.0001).
Smoking remained a risk factor for mortality across increasing strata of CAC scores (1 to 100, 101 to 400, and400).
At each stratum of elevated CAC score, mortality in smokers was consistently higher than mortality in nonsmokers
from the CAC stratum above. In multivariable analysis within these strata, we found mortality hazard ratios of 3.8
(95% conﬁdence interval [CI]: 2.8 to 5.2), 3.5 (95% CI: 2.6 to 4.9), and 2.7 (95% CI: 2.1 to 3.5), respectively, in smokers
compared with nonsmokers. However, among the 19,898 individuals with CAC 0, the mortality hazard ratio for
smokers without CAC was 3.6 (95% CI: 2.3 to 5.7), compared with nonsmokers without CAC.
CONC L U S I O N S Smoking is a risk factor for death across the entire spectrum of subclinical coronary
atherosclerosis. Smokers with any CAC had signiﬁcantly higher mortality than smokers without CAC, a ﬁnding with
implications for smokers undergoing lung cancer CT-based screening. However, the absence of CAC might not be
as useful a “negative risk factor” in active smokers, because this group has mortality rates similar to nonsmokers
with mild-to-moderate atherosclerosis. (J Am Coll Cardiol Img 2012;5:1037–45) © 2012 by the American College
of Cardiology Foundation
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1038moking is a leading contributor to cardio-
vascular disease worldwide. Among Ameri-
cans18 years of age, 23% of men and 18%
of women smoke (1). Although public
ealth laws have helped curb smoking rates in
estern populations (2), tobacco companies con-
inue to aggressively advertise in Third World
ountries. Consequently, an estimated 1.3 billion
eople now smoke worldwide (1). Smokers have
ncreased all-cause mortality, and it is estimated
hat up to 40% of this mortality is attributable to
ardiovascular events (3).
Smoking exerts numerous pathological effects,
ncluding increases in endothelial dysfunction (4),
latelet reactivity (5), and systemic markers of
nflammation (including C-reactive protein) (6).
hese aberrations accelerate the development of
oth clinical and subclinical atherosclerosis in
mokers (7). For instance, smoking has been
trongly associated with both baseline coronary
rtery calcium (CAC) (8) and CAC progression
(9,10), as measured by cardiac computed
tomography (CT).
However, the interaction between smok-
ing and CAC has not been fully elucidated.
Although it is known that smoking remains
an independent risk factor for mortality after
accounting for subclinical coronary athero-
sclerosis (8), a number of important ques-
tions remain. Is CAC a similarly good pre-
dictor of mortality among both nonsmokers
and smokers? Prior studies have not specif-
ically addressed this issue (8). Similarly,
hat are the relative risks of increasing levels of
aseline CAC in smokers as compared with
onsmokers? Also, is mortality in smokers with a
alcium score of zero (CAC  0) higher than has
een reported in the general population with
AC  0 (11)?
With new evidence demonstrating a prognostic
enefit for CT-based lung cancer screening in
mokers (12), the mortality differences between
he absence or presence of coronary calcification
n smokers is of increasing clinical relevance. This
uestion is particularly important, because smok-
rs with CAC  0 might harbor noncalcified
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We sought to address these questions in the
argest follow-up of CAC scanning yet undertaken.
M E T H O D S
The study cohort consisted of 44,042 consecutive
asymptomatic individuals, free of known coronary
heart disease (CHD), referred by their physicians
for electron beam tomography (EBT) to help refine
individual CHD risk prediction. Patients were pre-
sumed to be free of clinical CHD on the basis of a
clinical history, which was conducted by the refer-
ring physician. The dataset for this study represents
the combination of data collected between 1991
and 2004 from 3 different centers in the United
States (Nashville, Tennessee; Columbus, Ohio; and
Torrance, California). The combined population
was predominantly of Caucasian ethnicity.
All screened individuals provided informed con-
sent to undergo EBT and for the use of their
blinded data for epidemiologic research. The gen-
eral study received approval from the Human In-
vestigations Committee, and separate Committee
approval was obtained for patient interviews, col-
lection of baseline and follow-up data, and corrob-
oration of the occurrence of death.
Risk factor data collection. All study participants
ere given a questionnaire for the collection of
emographic characteristics as well as baseline car-
iovascular risk factors. The following risk factors
ere considered in our study: 1) cigarette smoking
as considered present if a subject was an active
moker at the time of scanning; 2) dyslipidemia was
onsidered to be present for any individual report-
ng a history of high total cholesterol, high low-
ensity lipoprotein cholesterol, low high-density
ipoprotein cholesterol, high triglycerides, or cur-
ent use of lipid-lowering therapy; 3) diabetes was
efined as baseline use of oral anti-diabetes medi-
ations or insulin; 4) hypertension was defined as a
elf-reported history of high blood pressure or the
se of antihypertensive medication; and 5) family
istory of premature CHD was determined by
sking patients whether any member of their im-
ersonville, Tennessee; and the ‡‡Section of
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1039mediate family (parents or siblings) had a history of
fatal or nonfatal myocardial infarction and/or cor-
onary revascularization in a male relative 55 years
or a female relative65 years in 36,010 (82% of the
study population), whereas the age cutoff was 55
years of age in both male and female relatives in
8,042 participants recruited from the Columbus
center (18% of the study population).
EBT screening protocol. All subjects underwent EBT
n either a C-100 or C-150 Ultrafast CT scanner
GE-Imatron, South San Francisco, California).
ith a tomographic slice thickness of 3 mm, a total
f approximately 40 sections were obtained begin-
ing at the level of the carina and proceeding
audally to the level of the diaphragm. Images were
btained with a 100-ms/slice scanning time, with
mage acquisition electrocardiographically triggered
t 60% to 80% of the R-R interval.
A calcified lesion was defined as 3 contiguous
ixels with a peak attenuation of at least 130
ounsfield units. Each lesion was then scored with
he method developed by Agatston et al. (14)
Agatston units).
Follow-up and mortality ascertainment. Patients were
ollowed for a mean of 5.6  2.6 years (range 1 to
3 years). The primary endpoint was all-cause
ortality. Ascertainment of mortality was con-
ucted by individuals blinded to baseline historical
ata and EBT results, and was verified using the
ocial Security Death Index. The United States
ocial Security Death Index is a national registry of
ll deaths that occur within the United States,
llowing for mortality ascertainment in 100% of
tudy participants.
Statistical methods. The baseline characteristics of
he study population are presented by smoking
tatus. Age is presented as a continuous measure 
D, and other risk variables are expressed as pro-
ortional frequencies. Age was compared across
ncreasing CAC groups with analysis of variance
echniques, and proportional frequencies of other
isk variables were compared across increasing
AC groups with chi-square analysis. A p value
0.05 was considered statistically significant.
Annualized all-cause mortality rates were esti-
ated by dividing the number of deaths by the
umber of person-years at risk. Mortality rates were
rst expressed for each CAC stratum group (0, 1 to
00, 101 to 400, and 400) and then stratified
ccording to smoking status.
In addition, survival analysis was conducted with
ndividual subject time to all-cause mortality data.
urves representing the cumulative probability ofurvival were generated with Kaplan-Meier esti-
ates. Hazard ratios (HRs) and 95% confidence
ntervals (CIs) for all-cause mortality were calcu-
ated for each CAC stratum with the Cox propor-
ional hazards regression model, with CAC  0 as
he reference group. Two hierarchical models were
onstructed: Model 1: adjusted for age and sex; and
odel 2: adjusted for age, sex, hypertension, dys-
ipidemia, diabetes mellitus, and family history of
HD. Schoenfeld residuals were calculated and
isually interpreted to evaluate the validity of pro-
ortional hazards assumption. Interaction terms for
ex and smoking in each CAC group were tested
nd discarded because of nonsignificance.
All statistical analyses were performed with
TATA version 10 (StataCorp, College Station,
exas).
R E S U L T S
Clinical characteristics of the cohort. The final study
population consisted of 44,042 asymptomatic indi-
viduals free of known cardiovascular disease before
EBT. The average age was 54  10 years. Approx-
mately 14% of subjects were smokers (6,020 smok-
rs, and 38,022 nonsmokers). Despite being
ounger on average, smokers had a greater number
f cardiac risk factors as compared with nonsmokers
2.1  1.2 vs. 0.8  0.7, p  0.0001) (Table 1).
All-cause mortality in smokers and nonsmokers.
There were 901 deaths (2.05%) in the study cohort
overall. A total of 258 (4.29%) smokers died over
the mean follow-up of 5.6 years, as opposed to 643
(1.69%) nonsmokers (p  0.0001). The mean
annualized mortality rate was 10.99 deaths/1,000
person-years (95% CI: 9.63 to 12.30) for smokers
versus 2.86 deaths/1,000 person-years (95% CI:
2.64 to 3.09) among nonsmokers. Furthermore,
when the entire cohort was separated on the basis of
Table 1. Clinical Characteristics of Subjects With and Without a
History of Cigarette Smoking
Nonsmokers
(n  38,022, 86%)
Smokers
(n  6,020, 14%)
Age (yrs) 55 11 53 10
Female 45 57
Hypertension 33 41
Diabetes 5 10
Dyslipidemia 26 52
Family history of CHD 33 62
Values are mean  SD or %p Value
0.0001
0.0001
0.0001
0.0001
0.0001
0.0001CHD  coronary heart disease.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 0 , 2 0 1 2
O C T O B E R 2 0 1 2 : 1 0 3 7 – 4 5
McEvoy et al.
CAC and Mortality Rates in Smokers
1040cardiac risk-factor subsets, smokers had consistently
higher mortality rates than nonsmokers (Table 2).
In age-sex adjusted analysis (model 1), smoking
was associated with at least a 4-fold increase of
mortality (HR: 4.39, 95% CI: 3.78 to 5.10, p 
0.0001). The HR for all-cause mortality among
smokers was 3.73 (95% CI: 3.18 to 4.36), after
adjustment for other relevant demographic data and
cardiac risk-factors (model 2). There were no devi-
ations from the proportional hazards assumption in
any multivariable model.
All-cause mortality in smokers and nonsmokers, as
stratiﬁed by CAC. As shown in Figure 1, CAC  0
was found in 38% of smokers, as opposed to 46% of
nonsmokers (p  0.0001). CAC strata of 1 to 100,
101 to 400, and400 Agatston units were found in
31%, 17%, and 14% of smokers, respectively. In
comparison, the respective percentages were 32%,
12%, and 9% for nonsmokers.
We found that all-cause mortality rates were
higher in both smokers and nonsmokers as baseline
CAC score increased (Fig. 2). The lowest mortality
was observed in nonsmokers with CAC  0 (0.7
events/1,000 person years), whereas smokers with
CAC 400 had the highest all-cause mortality rate
(29.9/1,000 person years). Importantly, at each
stratum of CAC score the mortality in smokers was
Table 2. All-Cause Mortality Rates by Cigarette Smoking Status
Nonsmokers
Rate/1,000 Person-Yrs at Risk 95%
Entire cohort 2.86 2
Age
45 yrs 0.83 0
45–64 yrs 1.81 1
65 yrs 9.14 8
Sex
Female 2.11 1
Male 3.44 3
HTN
No 2.19 1
Yes 6.29 5
Diabetes mellitus
No 2.42 2
Yes 14.78 12
Dyslipidemia
No 2.67 2
Yes 3.64 3
Family history of CHD
No 2.63 2
Yes 3.53 3
CHD  coronary heart disease; CI  conﬁdence interval; HTN  hypertension.noted to be higher than that of nonsmokers in thenext highest CAC stratum (for example, smokers in
the CAC stratum of 1 to 100 had higher all-cause
mortality rates than nonsmokers in the CAC stra-
tum of 101 to 400). Among smokers who died,
CAC 400 was noted in 37% of participants at
100
90
80
70
60
50
40
30
20
10
0
%
p < 0.0001
CAC = 0 CAC 1-100 CAC 101-400 CAC > 400
Nonsmokers Smokers
Figure 1. CAC Severity on the Basis of Smoking Status
On the basis of pre-speciﬁed coronary artery calciﬁcation (CAC)
strata (1 to 100, 101 to 400, and 400 Agatston units), we
found increased prevalence and severity of calciﬁed subclinical
atherosclerosis in smokers than in nonsmokers. These CAC strata
of 1 to 100, 101 to 400, and 400 Agatston units were found in
31%, 17%, and 14% of smokers, respectively. In comparison, the
tratiﬁed by Cardiac Risk-Factor Subsets
Smokers
for Rate Rate/1,000 Person-Yrs at Risk 95% CI for Rate
3.09 10.99 9.63–12.30
1.16 5.41 3.66–8.02
2.04 7.72 6.46–9.23
10.16 33.16 27.54–39.94
2.42 9.02 7.53–10.81
3.78 13.15 11.15–15.53
2.42 8.21 6.85–9.83
7.16 15.04 12.73–17.75
2.63 9.93 8.67–11.35
17.69 20.37 15.16–27.38
2.93 11.86 10.07–13.97
4.25 9.84 8.18–11.84
2.89 12.45 10.39–14.93
4.05 9.84 8.33–11.61as S
CI
.64–
.60–
.60–
.22–
.84–
.13–
.99–
.53–
.22–
.34–
.45–
.10–
.39–
.08–respective percentages were 32%, 12%, and 9% for nonsmokers.
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1041baseline as compared with 13% of smokers who
survived (p  0.0001).
With Cox proportional hazards regression, ad-
usting for demographic data and CHD risk factors,
e found that increasing CAC scores (1 to 100, 101
o 400, and 400) were associated with increased
azard of all-cause mortality among both smokers
s well as nonsmokers, compared with CAC  0.
However, the respective mortality HRs as CAC
group increased were 2.0- to 4.3-fold among smok-
ers and slightly higher at 2.6- to 8.0-fold among
nonsmokers (Table 3). In keeping with this, the
smoking-CAC group interaction term was negative
(HR of 0.75, p  0.001), suggesting that the
association of smoking with mortality was weaker in
higher CAC groups.
In Table 4 we take a different perspective. Instead
f using CAC to stratify mortality in both smokers
nd nonsmokers as independent groups (Table 3),
30
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Figure 2. Mortality Rates (1,000 Person-Years) According to Sm
The lowest mortality rate was observed in nonsmokers without cor
whereas smokers with CAC 400 had the highest all-cause mortali
score, the mortality in smokers was noted to be higher than that o
CAC stratum of 1 to 100 had higher all-cause mortality rates than n
Table 3. All-Cause Mortality HRs in Subjects With Elevated
Baseline CAC Compared With Baseline CAC  0
Nonsmokers
(n  38,022, 86%)
Smokers
(n  6,020, 14%)
HR (95% CI) HR (95% CI)
CAC 0 Ref* Ref†
CAC 1–100 vs. 0 2.62 (1.99–3.45)* 2.04 (1.10–1.83)†
CAC 101–400 vs. 0 4.15 (3.11–5.54)* 2.57 (1.62–4.05)†
CAC 400 vs. 0 8.04 (6.09–10.61)* 4.25 (2.72–6.63)†
Stratiﬁed by cigarette smoking status. Adjusted for age, sex, dyslipidemia,
diabetes mellitus, HTN, and family history of CHD. *Comparing strata of
positive coronary artery calciﬁcation (CAC) with CAC  0 in nonsmokers.
†Comparing strata of positive CAC with CAC  0 in smokers.HR  hazard ratio; other abbreviations as in Table 2.e now compare the mortality hazard of smoking
ompared to nonsmoking in each of the different
trata of baseline CAC. This allows us to explore
he potential effect of smoking at each level of CAC
everity. We found that at each stratum of baseline
AC elevation, smokers had higher mortality HRs
n multivariate analysis than nonsmokers (Table 4).
hus, baseline CAC accurately stratified HRs in
oth smokers and nonsmokers, but at each stratum
f CAC score that hazard was higher in the
moking group when directly compared with the
onsmoking group. The CAC also added signifi-
antly to the prediction of all-cause mortality
mong smokers, beyond traditional risk factors (chi
quare  47.80, p  0.0001).
We found that the percentage of female smokers
ith CAC0 was 65%, as opposed to 57% of male
mokers. However, the multivariate-controlled all-
ause mortality HR for female smokers was 3.80
95% CI: 2.96 to 4.87) and for male smokers was
.66 (95% CI: 2.98 to 4.48), compared with their
espective nonsmoking counterparts. The smoking–
CAC 101-400 CAC > 400
g Status and CAC
y artery calciﬁcation (CAC) (0.7 events/1,000 person years),
te (29.9/1,000 person years). Importantly, at each stratum of CAC
nsmokers in the CAC stratum above (for example, smokers in the
mokers in the CAC stratum of 101 to 400).
Table 4. All-Cause Mortality HRs in Smokers as Compared
With Nonsmokers
HR for Smoking (95% CI)
CAC 0 3.62 (2.28–5.75)
CAC 1–100 3.84 (2.82–5.22)
CAC 101–400 3.54 (2.57–4.89)
CAC 400 2.71 (2.12–3.48)
Stratiﬁed by baseline CAC scores. Adjusted for age, sex, dyslipidemia, diabetes
mellitus, and family history of CHD.0
okin
onar
ty ra
f noAbbreviations as in Tables 2 and 3.
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1042sex interaction term was statistically nonsignificant
(p  0.91), suggesting similar effect across sex.
Outcomes in smokers with CAC  0 at baseline.
Smokers with CAC  0 had an all-cause mortality
ate of 3.31 deaths/1,000 person-years (95% CI:
.31 to 4.74). This was in contrast to 0.67 deaths/
,000 person-years for nonsmokers with CAC  0
(95% CI: 0.53 to 0.84). In the 19,898 individuals
with CAC  0, mean 5.6-year all-cause survival
as 99.6% for nonsmokers and 98.7% for smokers
p 0.001). Figure 3 demonstrates a Kaplan-Meier
urvival curve, on the basis of Cox proportional
azards cumulative survival, for nonsmokers and
mokers among those with CAC  0 (chi-square
ikelihood ratio  32.2, p  0.0001). In our
ultivariable analysis, the HR for mortality in
mokers without CAC was 3.62 (95% CI: 2.28 to
.75), compared with nonsmokers without CAC.
D I S C U S S I O N
In this combined cohort of 44,042 middle-aged
subjects, free of known CHD and followed for a
mean of 5.6 years, we found that CAC is an
independent predictor of all-cause mortality in both
smokers and nonsmokers. Importantly, at each
respective stratum of baseline CAC score, smokers
were consistently found to have higher mortality
rates than nonsmokers in the next highest CAC
Logrank p < 0.0001
1.00
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Figure 3. Survival in Nonsmokers and Smokers With CAC  0
This is a Kaplan-Meier survival curve among those with coronary ar
the 19,898 individuals with CAC  0, mean 5.6-year survival was 99
ratio for mortality in smokers without CAC was 3.62 (95% conﬁdenc
Although the event rates are low and the absolute survival differen
small, our results demonstrate that the absence of CAC might not bstratum. Sex did not influence the mortality effect of smoking on CAC in our study. However, smokers
with CAC  0 were also shown to have higher
relative mortality than nonsmokers with CAC  0.
These findings highlight the importance of smok-
ing cessation even in those without measurable
evidence of subclinical atherosclerotic disease.
Smoking and atherosclerosis. Our findings are con-
istent with the known effect of smoking on mor-
ality (3) and add to the findings of prior research
valuating the interplay between smoking and ath-
rosclerosis. Prior studies have associated pack-
ears of smoking exposure with the severity of
ngiographically determined atherosclerosis (15).
igarette smoking is a known independent predic-
or of new coronary atherosclerosis formation (16).
imilarly, smoking is a well-documented risk factor
or increased CAC, as assessed by cardiac CT (9).
Clinical effects of smoking and CAC. The largest study
o date analyzed a patient registry of 10,377 asymp-
omatic individuals undergoing EBT, with a
ollow-up of 5 years (8). This cohort had a high
revalence of smoking (40%), considerably higher
han our cohort and current national trends (1).
urvival was 98.4% in nonsmokers, compared with
6.9% in smokers. Multivariable relative risk ratios
or mortality in smokers were elevated 1.8-, 2.1-,
.5-, and 4.5-fold higher for patients with CAC
cores of 11 to 100, 101 to 400, 401 to 1,000, and
ime (Years)
LR   2 = 32.2
14068 7326 4134
1022 175 8
4 6 8
mokers Smokers
χ
calciﬁcation (CAC)  0, comparing nonsmokers with smokers. In
for nonsmokers and 98.7% for smokers (p  0.001). The hazard
terval: 2.28 to 5.75) compared with nonsmokers without CAC.
between smokers and nonsmokers in the CAC  0 subgroup are
s reassuring in those who smoke. LR  log-rank.T
Nons
tery
.6%
e in
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1043scores of 0 to 10). However, this study did not focus
on those with CAC  0 (8). In addition, we
provide CAC-stratified mortality data for non-
smokers as well as smokers, facilitating a direct
comparison between these 2 groups.
Although we found that HRs for mortality did
increase with each stratum of increasing baseline
CAC in smokers, we also found that these increases
were smaller in magnitude than the respective HRs
for nonsmokers in our cohort (Table 3). This
finding is likely due to the increased all-cause
mortality rates in the HR comparator groups of
CAC  0 in smokers than in nonsmokers (3.3 vs.
0.7 deaths/1,000 patient years, respectively) (Fig. 2).
Also contributing to this was the finding of a
negative interaction between smoking status and
CAC group. In such, smoking has less effect on
mortality as baseline CAC increases. We hypothe-
size that this is because much of the bad effects of
smoking over a lifetime are “taken into account” by
the high baseline CAC.
Importantly, baseline CAC severity does not
fully explain the mortality risk of smoking. Indeed,
when we controlled for baseline CAC in the mul-
tivariate analysis, we found that the HR for mor-
tality remained significantly elevated at 3.31 (95%
CI: 2.83 to 3.87, p  0.00001) for smokers com-
pared with nonsmokers. This finding should be
interpreted in the context of our study endpoint of
all-cause mortality, which incorporates noncardiac
causes of death. However, direct comparison of
mortality HRs between smokers and nonsmokers
found a similar magnitude of excess relative risk in
smokers as each stratum of baseline CAC score
increased (Table 4). This suggests that the relative
effect of smoking was similar at each stratum of
baseline CAC score.
Smoking in the absence of subclinical atherosclerosis.
Although CAC  0 might be thought of as a
“negative” cardiac risk factor (11), our results dem-
onstrate that the absence of CAC might not be as
reassuring in those who smoke. Although the event
rates are low and the absolute survival differences
between smokers and nonsmokers in the CAC  0
ubgroup are small (Fig. 3), the calculated HR of
.62 for mortality is highly statistically significant
nd might translate into ongoing separation of the
aplan-Meier survival curves over longer follow-
p. Factors associated with an increased relative risk
f mortality in smokers without CAC might be
artly attributed to the potential presence of non-
alcified plaque, which might be more prone to
upture than calcified plaque (13). wOther explanations include the increased inci-
dence of malignant arrhythmias and stroke in
smokers as well as death from other causes, in
particular malignancies. Future study (which in-
cludes cause-of-death data) is needed to further
elucidate the importance of cardiac events related to
noncalcified plaque in smokers (as opposed to
noncardiac causes of death).
Clinical implications. Our findings have a number of
road implications for risk prediction and preven-
ive efforts in cardiology. Figure 2 demonstrates that
he mortality rates in smokers at a given stratum of
aseline CAC are higher than in nonsmokers in the
ext-higher CAC stratum. As such, risk among
mokers should be considered equivalent to those
ith higher subclinical atherosclerosis burden in the
bsence of smoking. Thus, we hope that the same
ense of clinical foreboding extended by physicians
o smokers with asbestos exposure also be extended
o smokers found to have a moderate-large burden
f CAC on testing.
Our findings also extend to those without calci-
ed subclinical atherosclerosis. Given the potential
or increased future use of CAC quantification to
ssess individual cardiac risk (17) as well as the
xpected increase in CT-based lung cancer screen-
ng in smokers (12), it is important to evaluate
hether all those with CAC  0 are uniformly at
ow risk for future events. Although longer
ollow-up will be needed to confirm our finding of
ncreased mortality in smokers with CAC  0
ompared with nonsmokers with CAC  0, it
eems prudent that the former group not be pres-
ntly considered as low risk as the latter. Similarly,
hose smokers found to have any coronary calcifi-
ation on chest CT imaging (for example, on the
asis of lung cancer CT screening) are at signifi-
antly increased future mortality risk compared with
hose without coronary calcification and should
ave their cardiac risk factors aggressively treated
Fig. 4).
We hope our findings might help animate smok-
ng cessation discussions in those who have under-
one CAC testing. However, whether CAC mea-
urement can improve smoking cessation rates
emains to be seen. The EISNER (Early Identifi-
ation of Subclinical Atherosclerosis by Noninva-
ive Imaging Research) trial (18) did not demon-
trate improved smoking cessation in those
andomized to undergo CAC testing. Unfortu-
ately, the study was underpowered for this partic-
lar issue, because the number of active smokers
as small (6% of the total study cohort).
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1044Study limitations. This is a post-hoc analysis, which
cannot assess causality. All patients were referred
for CAC screening and therefore do not represent a
random sample of the population.
Another potential weakness is the self-reporting
of risk factors. Data gathered by self-report are
limited by patient recall and thus subject to recall
bias. Although Hoff et al. (19) have shown a good
reliability of self-reported histories of CHD risk
factors in self-referred individuals for EBT scan-
ning, potential “residual confounding” (which
would possibly diminish the strength of association
of risk factors with mortality) cannot be ruled out.
Similarly, although the lack of a continuous risk
variable might decrease the precision of point esti-
mates of risk, the use of categorical risk factor data
has been validated as an approach to clinical risk
stratification (20).
Unfortunately, we also do not have cardiac-
specific mortality available. However, the examina-
tion of death from all causes might allow for a more
reliable prediction model without the possibility for
cause of death misclassification (21). We know
from prior population-based studies that cardiac
mortality accounts for approximately 35% of deaths
in smokers and 27% of deaths in nonsmokers in our
cohort age group (3).
In addition, we do not have data with regard to
the number of pack-years smoked and whether or
Logrank p < 0.0001
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Figure 4. Survival in Smokers Without CAC Versus Smokers Wit
Trial evidence demonstrates a prognostic beneﬁt for computed tom
might become much more widespread. Thus, the relative prognost
nary calciﬁcation on such screening are of clinical signiﬁcance. Smo
tality risk compared with those without CAC and would likely bene
Abbreviations as in Figure 3.not nonsmokers were ex-smokers or never smokedin the past. Such data might have provided further
insight into any dose-response relationship in this
cohort. We plan to study this relationship further in
the MESA (Multi-Ethnic Study of Atherosclero-
sis) study. It is of interest that several large epide-
miological studies have failed to find a significant
dose-dependent correlation between cardiovascular
risk and the pack-years of smoking exposure
(22,23).
Finally, we hypothesize that our results likely
represent an underestimation of the effect of smok-
ing. Population studies have shown that ex-smokers
have higher cardiovascular event rates than never-
smokers. Thus, the event rates reported in our
nonsmoking group might be higher than would be
truly seen in those who never smoked. The event
rates in our smoking group might also be an
underestimation of the effect of continuous smok-
ing exposure, because we were unable to distinguish
those who gave up smoking during our follow-up
from those who continued to smoke. This potential
underestimation of the effects of smoking in our
analysis adds poignancy to the adverse findings we
report above.
C O N C L U S I O N S
Smoking is an important mortality risk factor across
the entire spectrum of subclinical atherosclerosis,
Time (Years)
LR χ2 = 72.2
1022 175 8
1621 288 28
4 6 8
AC Any CAC
ny CAC
aphy-based lung cancer screening in smokers, and such screening
plications of visualizing any coronary calciﬁcation versus no coro-
with any CAC elevation are at signiﬁcantly increased future mor-
om more aggressive cardiac risk factor modiﬁcation.No C
h A
ogr
ic im
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ﬁt frincluding those with CAC  0. The absence of
C
S
M
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 0 , 2 0 1 2
O C T O B E R 2 0 1 2 : 1 0 3 7 – 4 5
McEvoy et al.
CAC and Mortality Rates in Smokers
1045CAC in smokers should not be regarded as a
“negative risk factor” until smoking cessation oc-
curs. Despite this, coronary artery calcification re-
mains an excellent way of risk stratifying both
nonsmokers and smokers. Whether CAC quantifi-
cation can motivate smoking cessation efforts de-
serves future study. Our data reinforce the notion
that all smokers, including those without subclinicalprogression: an important clinical
measurement? A review of published
1
1
1
1
1
1
1
17. Greenland P, Polon
a policy change foincreased CAC, should be strongly encouraged to
quit.
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